MedTrace Logo

Benralizumab Exacerbation Study

NCT04102800 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 157

Last updated 2024-04-25

No results posted yet for this study

Summary

This is an exploratory study, the focus of which is to understand the nature of asthma exacerbations that occur despite open label benralizumab therapy in severe eosinophilic asthma.

Conditions

Interventions

DRUG

Benralizumab

subcutaneous injection

Sponsors & Collaborators

  • University of Glasgow

    collaborator OTHER

  • AstraZeneca

    collaborator INDUSTRY

  • Queen's University, Belfast

    collaborator OTHER

  • Bosch Healthcare Solutions GmbH

    collaborator INDUSTRY

  • InHealthcare

    collaborator UNKNOWN

  • University of Leicester

    collaborator OTHER

  • University of Plymouth

    collaborator OTHER

  • Vitalograph

    collaborator UNKNOWN

  • NHS Greater Glasgow and Clyde

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-30
Primary Completion
2024-02-22
Completion
2024-04-23

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04102800 on ClinicalTrials.gov